Back to top

Atea Pharmaceuticals announces first patient dosed in Phase 3 C-FORWARD trial

Atea Pharmaceuticals (AVIR) announced that the first patient was dosed in the global Phase 3 C-FORWARD trial evaluating the combination regimen of ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Atea Pharmaceuticals, Inc. (AVIR)